Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)

  • Technology appraisal
  • TA302
  • Published: 
Download guidance (PDF)

Overview

NICE is unable to make a recommendation about the use in the NHS of canakinumab for systemic juvenile idiopathic arthritis because no evidence submission was received from the manufacturer of the technology.

Last reviewed: 27 November 2013

Next review: We will review this decision if the company decides to make a submission.